C

Cyclopharm Ltd
ASX:CYC

Watchlist Manager
Cyclopharm Ltd
ASX:CYC
Watchlist
Price: 1.38 AUD 0.73% Market Closed
Market Cap: 153.4m AUD
Have any thoughts about
Cyclopharm Ltd?
Write Note

Cyclopharm Ltd
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Cyclopharm Ltd
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
C
Cyclopharm Ltd
ASX:CYC
Accounts Payable
AU$6.1m
CAGR 3-Years
25%
CAGR 5-Years
13%
CAGR 10-Years
16%
R
Respiri Ltd
ASX:RSH
Accounts Payable
AU$1.9m
CAGR 3-Years
14%
CAGR 5-Years
2%
CAGR 10-Years
3%
ImpediMed Ltd
ASX:IPD
Accounts Payable
AU$1.6m
CAGR 3-Years
-3%
CAGR 5-Years
-8%
CAGR 10-Years
5%
Cochlear Ltd
ASX:COH
Accounts Payable
AU$303.2m
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
14%
Optiscan Imaging Ltd
ASX:OIL
Accounts Payable
AU$1m
CAGR 3-Years
28%
CAGR 5-Years
21%
CAGR 10-Years
5%
EMvision Medical Devices Ltd
ASX:EMV
Accounts Payable
AU$928.1k
CAGR 3-Years
39%
CAGR 5-Years
17%
CAGR 10-Years
N/A
No Stocks Found

Cyclopharm Ltd
Glance View

Market Cap
153.4m AUD
Industry
Health Care

Cyclopharm Ltd. is a radiopharmaceutical company, which engages in the diagnostic imaging in lung health. The company provides diagnostic imaging services specializing in lung health. The firm through its medical device and pharmaceutical products under the name of Technegas, which has become the industry in diagnostic functional lung imaging technology. The company distributes its products in approximately 60 countries throughout the world with over 1500 nuclear medicine departments utilizing Technegas. The firm formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Macquarie Medical Imaging (MMI) offers a range of diagnostic radiology, interventional radiology, nuclear medicine and molecular imaging services for inpatient and outpatients. Its Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC Intrinsic Value
2.01 AUD
Undervaluation 31%
Intrinsic Value
Price
C

See Also

What is Cyclopharm Ltd's Accounts Payable?
Accounts Payable
6.1m AUD

Based on the financial report for Jun 30, 2024, Cyclopharm Ltd's Accounts Payable amounts to 6.1m AUD.

What is Cyclopharm Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
16%

Over the last year, the Accounts Payable growth was -18%. The average annual Accounts Payable growth rates for Cyclopharm Ltd have been 25% over the past three years , 13% over the past five years , and 16% over the past ten years .

Back to Top